The invention provides new methods of administering alpha-lipoic acid to patients. A diffusion rate limiting matrix is utilized to buccally, lingually and/or sublingually deliver the alpha-lipoic acid acid. This limited release matrix is intended for general nutritional supplementation and/or the treatment of various physiological disorders, such as diabetic neuropathy. Due to its lingual nature, this rate limiting matrix can deliver approximately IV-equivalent plasma levels of thioctic acid and is not meant to be swallowed.
